What is a stock summary page? Click here for an overview.
Business Description
ProQR Therapeutics NV
NAICS : 541714
SIC : 2836
ISIN : NL0010872495
Description
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.68 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -0.68 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 115.4 | |||||
| 3-Year EBITDA Growth Rate | 32.8 | |||||
| 3-Year EPS without NRI Growth Rate | 31.9 | |||||
| 3-Year FCF Growth Rate | 0.4 | |||||
| 3-Year Book Growth Rate | -21.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -18.86 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -28.82 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 100 | |||||
| 14-Day RSI | 100 | |||||
| 12-1 Month Momentum % | 33.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.95 | |||||
| Quick Ratio | 3.95 | |||||
| Cash Ratio | 3.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.9 | |||||
| Shareholder Yield % | -42.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -162.77 | |||||
| Net Margin % | -146.89 | |||||
| FCF Margin % | -196.89 | |||||
| ROE % | -62.74 | |||||
| ROA % | -21.2 | |||||
| ROIC % | -60.06 | |||||
| 3-Year ROIIC % | 842.64 | |||||
| ROC (Joel Greenblatt) % | -173.34 | |||||
| ROCE % | -29.04 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.82 | |||||
| PB Ratio | 1.85 | |||||
| Price-to-Tangible-Book | 1.88 | |||||
| EV-to-EBIT | -1.03 | |||||
| EV-to-EBITDA | -1.14 | |||||
| EV-to-Revenue | 1.49 | |||||
| EV-to-Forward-Revenue | 17.16 | |||||
| EV-to-FCF | -0.67 | |||||
| Price-to-GF-Value | 0.25 | |||||
| Price-to-Net-Current-Asset-Value | 2.23 | |||||
| Price-to-Net-Cash | 2.36 | |||||
| Earnings Yield (Greenblatt) % | -96.91 | |||||
| FCF Yield % | -23.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ProQR Therapeutics NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 379.558 | ||
| EPS (TTM) (MXN) | -6.312 | ||
| Beta | 1 | ||
| 3-Year Sharpe Ratio | -0.1 | ||
| 3-Year Sortino Ratio | -0.12 | ||
| Volatility % | 33.33 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR (MXN) | 0.000032 | ||
| 20-Day SMA (MXN) | 36 | ||
| 12-1 Month Momentum % | 33.33 | ||
| 52-Week Range (MXN) | 27 - 36 | ||
| Shares Outstanding (Mil) | 105.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ProQR Therapeutics NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ProQR Therapeutics NV Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
ProQR Therapeutics NV Frequently Asked Questions
What is ProQR Therapeutics NV(MEX:PRQR)'s stock price today?
The current price of MEX:PRQR is MXN36.00. The 52 week high of MEX:PRQR is MXN36.00 and 52 week low is MXN27.00.
When is next earnings date of ProQR Therapeutics NV(MEX:PRQR)?
The next earnings date of ProQR Therapeutics NV(MEX:PRQR) is 2025-05-09 Est..
Does ProQR Therapeutics NV(MEX:PRQR) pay dividends? If so, how much?
ProQR Therapeutics NV(MEX:PRQR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers